Alisertib
id:
alisertib-210-1688443
title:
Alisertib
text:
Alisertib (MLN8237) is an orally available, investigational, reversible, ATP-competitive, selective aurora A kinase inhibitor developed by Takeda. Inhibition of Aurora Kinase A leads to disruption of mitotic spindle apparatus assembly, disruption of chromosome segregation, and inhibition of cell proliferation. Takeda investigated alisertib as a treatment for relapsed or refractory peripheral T-cell lymphoma and development was paused in 2015 till Puma Biotechnology licensed global rights to alis
brand slug:
wiki
category slug:
encyclopedia
description:
Selective aurora A kinase inhibitor
original url:
https://en.wikipedia.org/wiki/Alisertib
date created:
2014-01-18T00:17:14Z
date modified:
2024-09-11T18:28:06Z
main entity:
{"identifier":"Q15633917","url":"https://www.wikidata.org/entity/Q15633917"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/2/2f/Alisertib.svg","width":752,"height":347}
fields total:
13
integrity:
16